FDA warns companies over unapproved weight loss drug sales 

The Food and Drug Administration (FDA) said Tuesday in a statement it has sent warning letters to companies selling unapproved weight loss drugs. The letter went to Xcel Peptides, Swisschems, Summit Research and Prime Peptides, four online companies it said were selling unapproved GLP-1 drugs, including semaglutide and tirzepatide. Semaglutide is known for its use...

No comments

Read more